Page last updated: 2024-08-17

quinoxalines and ribavirin

quinoxalines has been researched along with ribavirin in 71 studies

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's48 (67.61)24.3611
2020's23 (32.39)2.80

Authors

AuthorsStudies
Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J1
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E1
Kwong, AD; Tong, X1
Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D1
Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E1
Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J1
Cornberg, M; Manns, MP1
Barr, E; Buti, M; Calleja, JL; DiNubile, MJ; Forns, X; Gilbert, C; Gordon, SC; Hofer, H; Howe, AY; Lawitz, E; Palcza, J; Robertson, MN; Wahl, J; Zuckerman, E2
Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H1
Brown, A; Gendrano, IN; Howe, A; Hwang, P; Lagging, M; Mantry, PS; Mobashery, N; Ramji, A; Robertson, M; Vierling, JM; Wahl, J; Weilert, F; Zhang, B1
Nelson, DR; Peter, J1
Asante-Appiah, E; Black, T; Bystol, K; Chase, R; Curry, S; Hazuda, D; Howe, AY; Ingravallo, P; Lahser, FC; Liu, R; McMonagle, P; Xia, E1
Aschenbrenner, DS1
Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E1
Aguilar, H; Asatryan, A; Gane, E; Hassanein, T; Kort, J; Kwo, PY; Lalezari, J; Lin, CW; Liu, R; Maliakkal, B; Mensa, FJ; Ng, TI; Poordad, F; Wang, S; Wyles, DL1
Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z1
Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K1
Alric, L; Kamar, N; Rostaing, L1
Barr, E; Black, S; Buti, M; Dutko, FJ; Gane, EJ; Gress, J; Haber, B; Kwo, P; Lin, L; Lupinacci, L; Pearlman, B; Peng, CY; Robertson, M; Serfaty, L; Shafran, S; Stryszak, P; Vierling, JM; Wahl, J1
Boyd, S; Harrington, PR; Komatsu, TE; Naeger, LK; O'Rear, JJ; Sherwat, A; Tracy, L1
Elbasha, E; Greaves, W; Nwankwo, C; Roth, D1
Boyd, SD; Harrington, PR; Komatsu, TE; Murray, J; Sherwat, A; Tracy, L; Viswanathan, P1
Asatryan, A; Bernstein, DE; Felizarta, F; Flamm, SL; Fried, MW; Gordon, SC; Kort, J; Landis, CS; Lin, CW; Liu, R; Lovell, SS; Mensa, FJ; Ng, TI; Poordad, F; Reindollar, RW; Sulkowski, MS1
Chen, H; Huang, P; Li, J; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y1
Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J1
Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y1
Lim, SG1
Agarwal, K; Aguilar, H; Asatryan, A; Dore, GJ; Felizarta, F; Gane, E; Gordon, SC; Hassanein, T; Kort, J; Kwo, PY; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Muir, AJ; Ng, TI; Overcash, JS; Poordad, F; Sulkowski, MS; Wang, S; Wyles, DL1
Asante-Appiah, E; Barr, E; Gane, E; Haber, B; Hwang, P; Luketic, V; Nahass, R; Robertson, M; Wahl, J1
Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM1
Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F1
Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E1
Asante-Appiah, E; Asselah, T; Barr, E; de Ledinghen, V; Gerstoft, J; Hwang, P; Nguyen, BY; Pockros, PJ; Reesink, H; Robertson, M; Serfaty, L; Talwani, R; Wahl, J1
Agarwal, K; Asante-Appiah, E; Barclay, S; Barr, E; Brown, AS; Collier, J; Cramp, ME; Du, J; Forton, DM; Foster, GR; Fox, R; Gilbert, CL; Gordon, F; Haber, B; Moreea, S; Mutimer, DJ; Robertson, MN; Rosenberg, WM; Ryder, SD; Ustianowski, A; Wahl, J1
Balart, L; Barr, E; Ghalib, R; Hanna, GJ; Hwang, P; Luketic, V; Nguyen, BY; Pearlman, B; Ravendhran, N; Robertson, M; Talwani, R; Vierling, J; Zamor, PJ1
Basile, M; Cicchetti, A; Drago, C; Favaretti, C; Kheiraoui, F; Rolli, FR; Ruggeri, M1
Arand, M1
Asante-Appiah, E; Barr, E; Black, T; Brunhofer, J; Galloway, A; Haber, B; Hwang, P; Lahser, F; Palcza, J; Robertson, M; Wahl, J1
Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M1
Sulkowski, MS1
Anton, MD; Badia, E; Bonacci, M; Calleja, JL; Carmona, I; Carrión, JA; Castellote, J; Castro Urda, JL; de la Vega, J; Diago, M; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; Gallego, A; García Buey, L; García, ND; García-Samaniego, J; Gea, F; Hernández-Conde, M; Llerena, S; Menéndez, F; Molina, E; Montoliu, S; Moreno-Palomares, JJ; Moreno-Planas, JM; Morillas, RM; Pascasio, JM; Perelló, C; Piqueras Alcol, B; Romero-Gómez, M; Rosales-Zabal, JM; Salmeron, FJ; Sánchez Ruano, JJ; Souto-Rodríguez, R1
Cenderello, G; Di Biagio, A; Taramasso, L1
Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S1
Pawlotsky, JM1
Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A1
Fried, MW; Hassan, MA; Hinestrosa, F; Jacobson, IM; Kort, JJ; Larsen, L; Lok, AS; Lu, W; Michael, LC; Morelli, G; Nelson, DR; Pearlman, BL; Peter, JA; Reddy, KR; Shiffman, ML; Sulkowski, MS; Vainorius, M; Wang, GP; Willner, I1
Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ1
Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C1
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX1
Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P1
Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A1
Khalil, H; Kim, NG; Kullar, R; Saab, S1
Bernhard, B; Stickel, F1
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C1
Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH1
Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S1
Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML1
Chan, C; Kulik, L; Martin, MT; Patel, S1
Sarrazin, C1
Dietz, J; Sarrazin, C1
Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R1
Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S1
Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT1
Bukh, J; Christensen, PB; Fahnøe, U; Madsen, LW; Pedersen, MS; Øvrehus, A1
Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S1
Calvaruso, V; Ceccherini-Silberstein, F; Craxì, A; Di Maio, VC; Di Marco, V; Ferraro, D; Gibilaro, G; La Mantia, C; Licata, A; Petta, S; Reina, G1
Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H1
Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J1
Christensen, PB; Dröse, S; Hansen, JF; Holm, DK; Madsen, LW; Røge, BT; Øvrehus, A1
Guo, M; Ke, L; Liu, J; You, R1

Reviews

10 review(s) available for quinoxalines and ribavirin

ArticleYear
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:7

    Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Hepatitis C virus: how to provide the best treatment with what I have.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult

2016
Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.
    Transplant international : official journal of the European Society for Organ Transplantation, 2016, Volume: 29, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Quinoxalines; Ribavirin; Sulfonamides; Transplant Recipients

2016
HCV management in resource-constrained countries.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine

2017
Treatment of hepatitis C virus genotype 4 in the DAA era.
    Virology journal, 2018, 11-22, Volume: 15, Issue:1

    Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2018
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Seminars in liver disease, 2019, Volume: 39, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2020
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization

2020
Treatment failure with DAA therapy: Importance of resistance.
    Journal of hepatology, 2021, Volume: 74, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2021
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
    Frontiers in public health, 2022, Volume: 10

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides

2022

Trials

27 trial(s) available for quinoxalines and ribavirin

ArticleYear
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
    Gastroenterology, 2014, Volume: 147, Issue:2

    Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Young Adult

2014
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Amides; Carbamates; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Interferons; Quinoxalines; Ribavirin; Sulfonamides

2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2015
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult

2015
Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:2

    Topics: Adult; Aged; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult

2016
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Jan-01, Volume: 62, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Salvage Therapy; Sulfonamides; Treatment Outcome

2016
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:10

    Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2016
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
    Gastroenterology, 2016, Volume: 151, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response

2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Gastroenterology, 2016, Volume: 151, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
    Journal of hepatology, 2016, Volume: 65, Issue:6

    Topics: Antiviral Agents; Benzofurans; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir

2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Gastroenterology, 2017, Volume: 152, Issue:1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Young Adult

2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Leucine; Liver Function Tests; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load; Young Adult

2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult

2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Journal of hepatology, 2017, Volume: 67, Issue:2

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Failure

2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2,
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:11

    Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine

2017
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 03-19, Volume: 66, Issue:7

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2018
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:9

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Internationality; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Young Adult

2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzofurans; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sofosbuvir

2018
[In process].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:8

    Topics: Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin

2016
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
    Drug and alcohol dependence, 2019, 01-01, Volume: 194

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Gastroenterology, 2019, Volume: 157, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2019
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:8

    Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides

2020
Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:11

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pilot Projects; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response

2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:6

    Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult

2021
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
    Viruses, 2022, 03-16, Volume: 14, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; COVID-19; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pandemics; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides

2022

Other Studies

34 other study(ies) available for quinoxalines and ribavirin

ArticleYear
Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Hepatitis C; Humans; Interferons; Quinoxalines; Ribavirin

2014
New kids on the block--step by step to an ideal HCV therapy.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides

2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Treatment Failure

2015
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:10

    Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides

2015
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Imidazoles; Mutation; Protease Inhibitors; Quinoxalines; Replicon; Ribavirin; Sulfonamides

2016
A New Treatment for Chronic Hepatitis C.
    The American journal of nursing, 2016, Volume: 116, Issue:5

    Topics: Antiviral Agents; Benzofurans; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin

2016
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology, 2017, Volume: 152, Issue:3

    Topics: Antiviral Agents; Benzofurans; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Polymorphism, Genetic; Quinoxalines; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins

2017
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:4

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; United States

2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
    Clinical drug investigation, 2017, Volume: 37, Issue:4

    Topics: Antiviral Agents; Benzofurans; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Treatment Outcome

2017
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
    Canadian journal of gastroenterology & hepatology, 2017, Volume: 2017

    Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Load

2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Gastroenterology, 2017, Volume: 152, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult

2017
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:10

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Failure; Treatment Outcome; Viral Load

2017
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
    The American journal of gastroenterology, 2018, Volume: 113, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Black or African American; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Failure; Young Adult

2018
Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:9

    Topics: Antiviral Agents; Benzofurans; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Italy; Markov Chains; Quality-Adjusted Life Years; Quinoxalines; Ribavirin; Sofosbuvir

2018
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.
    Antiviral therapy, 2018, Volume: 23, Issue:7

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Genetic; Quinoxalines; Recurrence; Ribavirin; Serine Proteases; Treatment Failure; Viral Load; Viral Nonstructural Proteins

2018
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 02-01, Volume: 68, Issue:4

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2019
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 02-01, Volume: 68, Issue:4

    Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Quinoxalines; Ribavirin; Sexual and Gender Minorities; Sulfonamides

2019
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Registries; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Treatment Outcome

2019
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2019
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Advances in therapy, 2020, Volume: 37, Issue:1

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2020
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:e1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
    Zeitschrift fur Gastroenterologie, 2020, Volume: 58, Issue:5

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult

2020
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan

2020
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    European journal of gastroenterology & hepatology, 2022, 01-01, Volume: 34, Issue:1

    Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response

2022
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4

    Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine

2021
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    Journal of hepatology, 2021, Volume: 75, Issue:1

    Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides

2021
Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    Journal of hepatology, 2021, Volume: 75, Issue:1

    Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides

2021
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
    Internal medicine (Tokyo, Japan), 2021, Nov-01, Volume: 60, Issue:21

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
    Journal of Korean medical science, 2021, May-31, Volume: 36, Issue:21

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2022, Volume: 54, Issue:8

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA; Sulfonamides

2022
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
    Zeitschrift fur Gastroenterologie, 2022, Volume: 60, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome

2022
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Dec-20, Volume: 29, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021